Role of GSK-3β in Regulation of Canonical Wnt/β-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer

被引:54
|
作者
Jain, Shelly [1 ]
Ghanghas, Preety [1 ]
Rana, Chandan [1 ]
Sanyal, S. N. [1 ]
机构
[1] Panjab Univ, Dept Biophys, Chandigarh 160014, India
关键词
Akt; beta-catenin; colorectal cancer; DMH; GSK-3; beta; PI3-K; NITRIC-OXIDE SYNTHASE; ABERRANT CRYPT FOCI; BETA-CATENIN; PHOSPHATIDYLINOSITOL; 3-KINASE/AKT; CYCLOOXYGENASE-2; INHIBITOR; COLORECTAL-CANCER; DOWN-REGULATION; APOPTOSIS; CELECOXIB; DICLOFENAC;
D O I
10.1080/07357907.2017.1337783
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-steroidal anti-inflammatory drugs (NSAIDs) are emerging as novel chemopreventive agents because of their ability in blocking cellular proliferation, and thereby tumor development, and also by promoting apoptosis. GSK-3 beta, a serine threonine kinase and a negative regulator of the oncogenic Wnt/beta-catenin signaling pathway, plays a critical role in the regulation of oncogenesis. Celecoxib and etoricoxib, the two cyclooxygenase-2 (COX-2) selective NSAIDs, and Diclofenac, a preferential COX-2 inhibitory NSAID, had shown uniformly the chemopreventive and anti-neoplastic effects in the early stage of colon cancer by promoting apoptosis as well as an over-expression of GSK-3 beta while down-regulating the PI3-K/Akt oncogenic pathway.
引用
收藏
页码:473 / 483
页数:11
相关论文
共 50 条
  • [31] α-Actinin-4 Promotes the Progression of Prostate Cancer Through the Akt/GSK-3β/β-Catenin Signaling Pathway
    Park, Sungyeon
    Kang, Minsoo
    Kim, Suhyun
    An, Hyoung-Tae
    Gettemans, Jan
    Ko, Jesang
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [32] Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3β-mediated phosphorylation of β-catenin
    Haraguchi, K.
    Ohsugi, M.
    Abe, Y.
    Semba, K.
    Akiyama, T.
    Yamamoto, T.
    ONCOGENE, 2008, 27 (03) : 274 - 284
  • [33] Ajuba negatively regulates the Wnt signaling pathway by promoting GSK-3β-mediated phosphorylation of β-catenin
    K Haraguchi
    M Ohsugi
    Y Abe
    K Semba
    T Akiyama
    T Yamamoto
    Oncogene, 2008, 27 : 274 - 284
  • [34] Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells
    Wang, QD
    Wang, XF
    Hernandez, A
    Hellmich, MR
    Gatalica, Z
    Evers, BM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (39) : 36602 - 36610
  • [35] Inhibition of GSK-3β accelerates bone formation via the activation of the Wnt/β-catenin signaling pathway
    Arioka, Masaki
    Takahashi, Fumi
    Sasaki, Masanori
    Sasaguri, Toshiyuki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 115P - 115P
  • [36] Involvement of GSK-3β Phosphorylation Through PI3-K/Akt in Cerebral Ischemia-Induced Neurogenesis in Rats
    Keishi Kisoh
    Hideki Hayashi
    Tsuyoshi Itoh
    Mayumi Asada
    Miho Arai
    Bo Yuan
    Kouichi Tanonaka
    Norio Takagi
    Molecular Neurobiology, 2017, 54 : 7917 - 7927
  • [37] Involvement of GSK-3β Phosphorylation Through PI3-K/Akt in Cerebral Ischemia-Induced Neurogenesis in Rats
    Kisoh, Keishi
    Hayashi, Hideki
    Itoh, Tsuyoshi
    Asada, Mayumi
    Arai, Miho
    Yuan, Bo
    Tanonaka, Kouichi
    Takagi, Norio
    MOLECULAR NEUROBIOLOGY, 2017, 54 (10) : 7917 - 7927
  • [38] Sulforaphane Ameliorates the Intestinal Injury in Necrotizing Enterocolitis by Regulating the PI3K/Akt/GSK-3β Signaling Pathway
    Bao, Zhong-Kun
    Mi, Yan-Hong
    Xiong, Xiao-Yu
    Wang, Xin-Hong
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 2022
  • [39] PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3β signaling pathway in DMH induced early colon carcinogenesis in rat
    Saini, Manpreet Kaur
    Sanyal, Sankar Nath
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2012, 93 (01) : 135 - 146
  • [40] Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3β signaling pathway
    Wei, Hongtao
    Duan, Guanghui
    He, Jianxun
    Meng, Qinglong
    Liu, Yuxian
    Chen, Wanqiang
    Meng, Yongpeng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (01) : 1136 - 1142